How chronic cough has emerged as a discrete indication with its own pipeline

What chronic cough is and why it is now an indication

Chronic cough is defined as a cough lasting more than eight weeks (in adults) without an identifiable underlying treatable cause. It affects a substantial portion of the population and is associated with material quality-of-life impact, sleep disturbance and social dysfunction.

Historically, chronic cough was managed by treating presumed underlying causes (asthma, GERD, postnasal drip, ACE inhibitor side effects) and by symptomatic approaches (cough suppressants, opioids in refractory cases). It was not treated as a discrete indication with dedicated pharmacology.

The emergence of P2X3 receptor antagonism as a mechanism specifically targeting cough hypersensitivity has changed this. P2X3 receptors are expressed on vagal afferent neurons that mediate cough; antagonism modulates the cough reflex pathway directly without targeting underlying respiratory or gastrointestinal pathology.

What is now in the indication

The pipeline as of mid-2026:

• Approved P2X3 antagonists: Multiple P2X3 receptor antagonists across major markets, with refined selectivity profiles to mitigate the taste-disturbance side effect that affected the first-generation
• Late-stage P2X3 programs: Next-generation P2X3 antagonists with improved tolerability profiles
• Adjacent neural-pathway mechanisms: Targeting other neural receptors involved in cough hypersensitivity (NK1, TRPV1, alternative ion-channel programs)
• Anti-inflammatory programs: Targeting cough-associated inflammation in specific patient profiles

What this means for commercial planning

The transition of chronic cough from symptom-management to discrete-indication has commercial implications:

• Patient-finding pathway: Chronic cough patients have historically been distributed across primary care, pulmonology, ENT, gastroenterology, and allergy clinics. Reaching the eligible population requires engagement across all these settings
• Reimbursement framing: The indication-specific framing supports payer coverage in a way that the symptom-management framing did not. The framework varies by market
• Real-world evidence base: The category is being built. Real-world cough-frequency endpoints, validated patient-reported outcome measures, and longitudinal cohort data are all being established as the indication matures
• Differential diagnosis: The eligible population needs to be distinguished from underlying-cause cough; the diagnostic pathway is operationally important

What we are watching

• Late-stage P2X3 pipeline programs with refined tolerability profiles
• Adjacent neural-pathway mechanism programs and the rate of indication validation
• Real-world utilisation patterns and the rate of patient-finding pathway maturation
• Adjacent symptom-driven indications attempting similar repositioning to discrete-indication status (chronic itch, chronic pain syndromes, chronic dyspnoea)